|
| Press Releases |
|
 |
|
| Friday, October 25, 2024 |
|
|
Everest Medicines Announces the Launch of VELSIPITY(R) in the Guangdong-Hong Kong-Macau Greater Bay Area |
| Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that, through the "Hong Kong and Macau Medicine and Equipment Connect" policy, VELSIPITY(R) has officially been approved for patients with moderately to severely active ulcerative colitis (UC) by the Guangdong Provincial Medical Products Administration and can first be used in the Foshan Fosun Chancheng Hospital and the First Affiliated Hospital of Sun Yat-sen University, two of the medical institutions designated by the "Hong Kong and Macau Medicine and Equipment Connect" policy in the Greater Bay Area. more info >> |
|
| Tuesday, October 22, 2024 |
|
|
Everest Medicines Announces Positive Results of Complete Chinese Subpopulation Data from the NEFECON Global Phase 3 NefIgArd Clinical Trial |
| Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that the "Kidney 360" magazine has published the complete two-year subpopulation data from Chinese patients in the Phase 3 NefIgArd clinical trial of NEFECON under the title "Efficacy and Safety of Nefecon in Patients With Immunoglobulin A Nephropathy From Mainland China: 2-Year NefIgArd Trial Results". more info >> |
|
| Monday, October 21, 2024 |
|
|
Everest Medicines Announces Taiwan TFDA Approval of NEFECON for the Treatment of Primary IgA Nephropathy |
| Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announces that the Taiwan Food and Drug Administration (TFDA) has approved NEFECON indicated "to reduce the loss of kidney function in adult patients with primary immunoglobulin A nephropathy (IgAN) who are at risk for disease progression1". There are no restrictions on initial proteinuria levels in the approved indication. more info >> |
|
| Friday, October 18, 2024 |
|
|
Everest Medicines' Stock Price Rises by 20% as Profit Potential Drives Valuation Recovery |
| Everest Medicines (1952.HK) closed today with a 20.46% increase, hitting a high of HKD 28.6. The company's stock price has been steadily rising since the release of its interim results, with today's trading volume reaching HKD 291 million. Market updates show that BOCOM International released a report assigning an 'outperform' rating to the Chinese pharmaceutical sector, with Everest Medicines being one of the key recommended stocks. more info >> |
|
| Wednesday, October 2, 2024 |
|
|
NEFECON Included in 2024 KDIGO Clinical Practice Guidelines |
| Recently, Everest Medicines has announced another positive development. The company's lead product, NEFECON, as the only in-disease IgA nephropathy (IgAN) treatment, has been included in the "KDIGO 2024 Clinical Practice Guideline for the Management Of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV) (Public Review Draft)" (hereinafter referred to as the "New Guidelines (Draft)"), recommending treatment with a 9-month course of NEFECON for patients who are at risk of progressive kidney function loss with IgAN (2B). more info >> |
|
| Thursday, August 22, 2024 |
|
|
Everest Medicines Announces the Initiation of an Investigator-Initiated Clinical Trial (IIT) |
| Everest Medicines (HKEX 1952.HK, 'Everest', or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced the launch of an Investigator-Initiated Clinical Trial (IIT) for a personalized mRNA cancer vaccine, EVM16, under the study EVM16CX01, at the Peking University Cancer Hospital and Fudan University's Cancer Hospital. more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
Open World and VerifyMe Sign Merger Agreement
Feb 12, 2026 21:00 HKT/SGT
|
|
|
U.S. Polo Assn. Unveils Experiential USPA Shop Flagship at the USPA National Polo Center
Feb 12, 2026 20:00 HKT/SGT
|
|
|
Radisson Highlights Developing Vein Model at O'Brien Gold Project with Implications for Future Growth and Mine Planning
Feb 12, 2026 19:59 HKT/SGT
|
|
|
Lockheed Martin and Fujitsu Formalize Industrial Collaboration for Japan Defense
Feb 12, 2026 19:59 JST
|
|
|
Meiji and Fujitsu launch world's first rRAFU(TM) pilot to assess future malnutrition and frailty risk
Feb 12, 2026 16:09 JST
|
|
|
Airwheel Announces Expanded Global Deployment of AI-Enabled Rideable Smart Electric Cabin Suitcase
Feb 12, 2026 11:30 HKT/SGT
|
|
|
Fujitsu Group starts manufacturing sovereign AI servers in Japan to enhance digital sovereignty
Feb 12, 2026 12:13 JST
|
|
|
Casa Minerals Inc Announces Closing of Oversubscribed Private Placement, and Retains European Marketing Firm for Investor Awareness Services
Feb 12, 2026 07:30 HKT/SGT
|
|
|
GTJAI Sponsored Axera's Listing on the Main Board of HKEX
Feb 11, 2026 19:40 HKT/SGT
|
|
|
Bioxytran Reports Positive Phase 2 Results Demonstrating Rapid Viral Clearance with ProLectin-MBioxytran
Feb 11, 2026 19:00 HKT/SGT
|
|
|
Focus Graphite Engages Dr. Reuter Investor Relations to Expand German and European Capital Markets Presence
Feb 11, 2026 18:29 HKT/SGT
|
|
|
CleverTap Recognized as a Leader in Latest Gartner Magic Quadrant for Personalization Engines
Feb 11, 2026 14:30 HKT/SGT
|
|
|
Premiere of Three-Row Highlander BEV in North America
Feb 11, 2026 14:25 JST
|
|
|
The 18th Annual Global CSR & ESG Summit & Awards 2026 Arrives in Bangkok -- Igniting Asia with AI, Energy & ESG Innovation on 23 April 2026
Feb 11, 2026 11:39 HKT/SGT
|
|
|
U.S. Marine Corps Selects GA-ASI for MUX TACAIR Collaborative Combat Aircraft Program
Feb 11, 2026 08:00 HKT/SGT
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
